Acrivon Therapeutics, Inc. (ACRV) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $41.50M | +4.2% |
| 2024 | $39.82M | +10.6% |
| 2023 | $36.02M | +22.0% |
| 2022 | $29.52M | -70.4% |
| 2021 | $99.60M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $41.50M | +4.2% |
| 2024 | $39.82M | +10.6% |
| 2023 | $36.02M | +22.0% |
| 2022 | $29.52M | -70.4% |
| 2021 | $99.60M | — |